Stage III Grade 3 Follicular Lymphoma Recruiting Phase 1 / 2 Trials for Rituximab (DB00073)

Indication	Status	Phase
DBCOND0028630 (Stage III Grade 3 Follicular Lymphoma)	Recruiting	1 / 2

clinicaltrials.gov Identifier	Title	Purpose	Drugs
NCT02213913	Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas	Treatment	Cefotaxime (DB00493) Cyclophosphamide (DB00531) Doxorubicin (DB00997) Etoposide (DB00773) Lenalidomide (DB00480) Prednisone (DB00635) Rituximab (DB00073) Vincristine (DB00541)
NCT01805037	Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas	Treatment	Brentuximab vedotin (DB08870) Rituximab (DB00073)